News

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...
Pfizer licenses 3SBio cancer drug for $1.25B upfront
Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug ...
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Key Takeaways Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe.Chinese firm 3SBio is developing a drug that is in trials to treat ...